0 Stock Overview
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Advanced Proteome Therapeutics Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0005 |
| 52 Week High | CA$0.095 |
| 52 Week Low | CA$0.0005 |
| Beta | 1.17 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -99.47% |
| 3 Year Change | -99.22% |
| 5 Year Change | -99.67% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | 1.1% |
| 1Y | -99.5% | -24.9% | 6.5% |
Return vs Industry: 0E81 underperformed the German Biotechs industry which returned -23.1% over the past year.
Return vs Market: 0E81 underperformed the German Market which returned 5.9% over the past year.
Price Volatility
| 0 volatility | |
|---|---|
| 0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.2% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 0E81 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0E81's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Paul John Woodward | www.advancedproteome.com |
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and immunomodulation.
Advanced Proteome Therapeutics Corporation Fundamentals Summary
| 0 fundamental statistics | |
|---|---|
| Market cap | €279.87k |
| Earnings (TTM) | -€1.89m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs 0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.04m |
| Earnings | -US$2.04m |
Last Reported Earnings
Apr 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.05 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -141.6% |
How did 0 perform over the long term?
See historical performance and comparison